News
-
According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz’s salmeterol/fluticasone DPI… Read more . . .
-
According to Mylan, the United States District Court for the Northern District of West Virginia has upheld the validity of all of its patents related to Perforomist formoterol fumarate inhalation solution. The company says that… Read more . . .
-
Israeli pharmaceutical company Kamada has initiated a US Phase 2 trial of its inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency, also known as inherited emphysema. The company also announced a delay in… Read more . . .
-
Medical Developments UK (MDUK) has announced that it will donate 25p from the sale of each of its pMDI spacers in the UK to Asthma UK. MDUK is part of Medical Developments International, whose Space… Read more . . .
-
CDMO Formex, formerly PharmaForm, has hired Steve Massah as President and CEO. Massah joins Formex from Gilead, where he worked in Strategic Drug Product Manufacturing and Outsourcing. He has previously held management positions with Avanir,… Read more . . .
-
According to St. Renatus, Blue Ocean Holdings is investing an additional $5 million in the company. The funds will go toward completion of St. Renatus’s New Drug Application (NDA) for its nasal mist dental anesthesia… Read more . . .
-
GSK and Theravance have announced that results from three phase 3 studies comparing the Anoro Ellipta umeclidinium/vilanterol DPI to Advair and Seretide Diskus in COPD patients show greater improvement in lung function for patients treated… Read more . . .
-
Alexza Pharmaceuticals has announced that its European partner Ferrer has launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients in Romania. Ferrer has a distribution agreement with Galenica for… Read more . . .
-
Vectura has announced that it will acquire Activaero for a total of €130 million ($181 million). The company cited both Activaero’s nebulizer technology and its pipeline of respiratory drugs as part of the rationale for… Read more . . .
-
The New York Times has reported that Hunein “John” Maassab, who developed the FluMist intranasal live attenuated influenza vaccine (LAIV), died on February 1, 2014 in North Carolina. Dr. Maassab received a doctorate in epidemiology… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland